Caxton Corp Allakos Inc. Transaction History

Caxton Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$1.72 - $3.18 $42,344 - $78,288	-24,619 Reduced 49.91%	24,710 $67,000
Q3 2023 Nov 14, 2023	BUY	$2.13 - $5.55 $67,299 - $175,357	31,596 Added 178.18%	49,329 $111,000
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $247,680 - $361,200	-68,800 Reduced 79.51%	17,733 $77,000
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $293,526 - $564,526	68,262 Added 373.61%	86,533 $385,000
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $103,413 - $153,841	18,271 New	18,271 $153,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.